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Introduction
In science as in life, timing is important. The dipeptide N-acetylaspartylglutamate (NAAG) was discovered in high concentration in the mammalian nervous system in the mid 1960s (Curatolo et al., 1965; Miyamoto et al., 1966) , a time when peptides were not considered to be significant contributors to communication among nerve cells and metabotropic neurotransmitter receptors had yet to be well recognized. Indeed, more than two decades passed before NAAG was identified in neurons (Anderson et al., 1986; Tieman et al., 1987) , and presynaptic vesicles (Williamson et al., 1988) , and the other criteria for characterization as a transmitter had been met (Neale et al., 2000) . The peptide also is reported to be present in and released from dendritic vesicles (Nordengen et al., 2019) . A nervous system enzyme activity that hydrolyzes NAAG was discovered (Riveros and Orrego, 1984) , purified (Slusher et al., 1990) and found to be expressed on the surface of glial cells (Cassidy and Neale, et al., 1993) providing a mechanism for NAAG inactivation following synaptic release. Sequencing studies (Bzdega et al., 1997; Luthi-Carter et al., 1998) revealed the identity of this enzyme activity to be that of a previously discovered protein termed prostate specific membrane antigen (PSMA) (O'Keefe et al., 1998) . Based on its enzyme activity, this protein was named glutamate carboxypeptidase II J o u r n a l P r e -p r o o f (GCPII) . The development of a potent GCPII inhibitor, 2-(phosphonomethyl)pentanedioic acid (PMPA) (Jackson et al., 1996) , provided the opportunity to examine for the first time the role of endogenous NAAG in an animal model of a human disorders (Slusher et al., 1999) . Following up on this concept, another highly potent inhibitor of GCPII, (N-[[[(1S) -1-carboxy-3methylbutyl]amino]carbonyl]-l-glutamic acid) (ZJ43) (Kozkowski et al., 2001) was characterized and has been used widely. Despite the substantial literature documenting the high levels and widespread distribution of this neuropeptide as well as its unique role in neuronal communication, it remains somewhat unrecognized in the broader neuroscience community and uncited in neuroscience texts.
NAAG at the cellular level
NAAG is the third most prevalent and widely distributed transmitter behind glutamate and GABA (Fuhrman et al., 1994) . The peptide is synthesized enzymatically (Cangro et al., 1987; Gehl et al., 2004; Collard et al., 2011; Lodder-Gadaczek et al., 2011) and co-expressed in neurons with several different primary amine transmitters, including glutamate and GABA.
While NAAG activates a limited subpopulation of NMDA receptors under some conditions (Khacho et al., 2015) but not others (Lea et al., 2001; Losi et al., 2004; Fricker et al., 2009) , its most studied functions are mediated by activation of the Group II metabotropic glutamate receptor mGluR3 and the subsequent inhibition of adenylate or guanylate cyclase (Wroblewska et al., 1998 (Wroblewska et al., , 2006 . This receptor is expressed by astrocytes (Wroblewska et al., 1998; Minoshima and Nakanishi, 1999) and has been localized on pre and post synaptic neurons as well (Chiechio, 2016) . While the actions of NAAG on astrocytes and post-synaptic neuronal sites have not been extensively studied, NAAG activation of presynaptic metabotropic receptors reduces corelease of small amine transmitters, including glutamate (Zhao et al., 2001; Sanabria et al., 2004; Romei et al., 2013) (Figure 1 ). Peptides are typically released under conditions of elevated excitability relative to their primary amine co-transmitters (Fulop et al., 2005) . Based on this model, NAAG release would be particularly important under conditions in which neuronal circuits are highly activated in that its inhibitory feedback process would increase the dynamic range of neuronal circuits where it is expressed. Several of the clinical models discussed below produce such high levels of neuronal activation. J o u r n a l P r e -p r o o f
Stroke, Traumatic Brain Injury and Peripheral Neuropathy
Stroke induced anoxia and traumatic brain injury result in the release of excitotoxic levels of glutamate with consequent neuronal and glial cell death. In the first studies to explore the role of NAAG in a clinical condition, it was discovered that the GCPII inhibitor 2-PMPA reduced ischemia-induced nerve cell death in a cerebral occlusion stroke model and in a primary cell culture (Slusher et al., 1999; Tortella et al., 2000) . Deletion of the GPCII gene also results in protection from ischemia (Bacich et al., 2005) . Following up on these observations, it was found that GCPII and mGluR3 are upregulated in a rat model of ischemia and that viral mediated knockdown of GCPII levels also reduces ischemia-induced apoptosis (Zhang et al., 2016) .
In the first studies of the role of NAAG in traumatic brain injury (TBI), treatment with the GCPII inhibitor (ZJ43) prior to injury significantly reduced hippocampal neuron and glial cell death (Zhong et al., 2005) . In parallel, it was found that treatment with this inhibitor increased extracellular NAAG levels while decreasing levels of glutamate and GABA in the immediate post injury hippocampus, consistent with the model of NAAG inhibition of release of small amine co-transmitters (Zhong et al., 2006) . Importantly in a critical test of the role of mGluR3 in this model, the neuroprotective efficacy of the peptidase inhibitor was blocked by coadministration of a group II mGluR (mGluR2/3) receptor antagonist. Treatment with a peptidase inhibitor following TBI also was efficacious (Feng et al., 2011 (Feng et al., , 2012 . As these results would predict, a heterotropic mGluR2/3 agonist also was found to be neuroprotective in a TBI model (Movsesyan and Faden, 2006) . Data confirming the role of a group II mGluR receptor in this process are particularly important given a report that NAAG inhibits NMDA receptors in the CA1 region of the hippocampus under some conditions (Khacho et al., 2015) . The neuronal sparing associated with GCPII inhibition has a demonstrable behavioral outcome in that the treatment reduces the motor and cognitive dysfunction that resulted from this trauma (Gurkoff et al., 2013) . As was observed in the brain ischemia models, GCPII knock out mice are less sensitive to TBI in terms of neuronal loss, oxidative stress and apoptosis (Gao et al., 2015; Cao et al., 2016) . In a different approach, transplantation into the brain of neural cells expressing high levels of NAAG synthetase reduced TBI-induced apoptosis, expression of inflammatory cytokines and motor deficits (Li et al., 2013) .
In the first test of the efficacy of GCPII inhibition in a model peripheral neuropathy, a single intravenous treatment ZJ43 or structurally related inhibitors reduced neuropathic pain J o u r n a l P r e -p r o o f perception induced by constriction injury (peripheral nerve ligation) in a mGluR2/3 dependent manner (Yamamoto et al., 2004) . In the same model, oral treatment with a 2-PMPA related inhibitor proved to be analgesic only after multiple daily doses (Vornov et al., 3013) , a result suggesting the possibility of a remedial action on the site of the trauma rather than simply a generalized analgesic action (see section 2.2 below). This long-term treatment also reversed changes in conduction velocity induced in the nerve constriction injury model (Wozniak et al., 2012) . GCPII inhibition reduced hyperalgesia, loss of nerve conduction velocity and myelinated fiber atrophy in the spontaneously diabetic (BB/Wor) rat (Zhang et al., 2002 (Zhang et al., , 2006 , reversed the adverse neuropathic effects of the chemotherapeutic agent oxaliplatin and reversed many of the effects of pyridoxine-induced neuropathy (Potter et al., 2014) . Taken together, these results suggest that GCPII inhibition may have applications across a broad array of neuropathic conditions.
NAAG Mediated Analgesia
As is the case with ischemic and traumatic brain injury, glutamate and glutamate receptors have long been associated with the pain perception axis (Pereira and Goudet, 2019) .
Both pro-and anti-nociceptive actions of glutamate receptor antagonists have been reported (Funytus et al., 2001) . The first evidence that inhibition of GCPII has analgesic potential was presented in a study of mechanical allodynia induced by injection of carrageenan into the rat footpad (Yamamoto et al., 2001) . Spinal (intrathecal) injection of 2-PMPA attenuated the allodynia as assessed with von Frey filaments. It was noted that the same drug treatment did not affect allodynia induced by a surgical incision or mild thermal injury to the footpad suggesting that the peptide moderates some but not all pain modalities. Following up on this study, it was found that intrathecal and intravenous treatment with ZJ-43 and a structurally related GCPII inhibitor suppressed the pain behavior induced by formalin injection into the rat footpad (Yamamoto et al., 2004) . These inhibitors also attenuated neuropathic pain induced by partial sciatic nerve ligation. Importantly, the analgesic effects were blocked by cotreatment with the selective mGluR2/3 antagonist LY-341495. Systemic ZJ43 treatment also reduced expression of the early immediate gene Fos in lamina I-II of the spinal cord in the formalin model. Since NAAG is expressed in a subpopulation of spinal sensory neurons (Cangro et al., 1987) and in a substantial number of spinal cord neurons (Moffett et al., 1993) , it is not possible to determine J o u r n a l P r e -p r o o f from these studies if the locus of analgesic action at the spinal level is pre-or post-synaptic to the sensory neuron or both. However, in an electrophysiology study of the effects of GCPII inhibition on spinal sensory afferents, 2-PMPA inhibited noxious evoked activity in C and Adelta fibers in controls and in the carrageenan footpad inflammation model (Carpenter et al., 2003) .
In a series of studies by Yamamoto's group, the analgesic efficacy of GCPII inhibition was tracked along the pain perception pathway. NAAG expression in dorsal sensory ganglion neurons led to speculation that it might be released peripherally. To determine if NAAG released from peripheral neurites has a role in the initial response of sensory neurons to painful stimuli, two group II mGluR agonists (Slx-3095 and APDC), NAAG, ZJ-43 and 2-PMPA were injected separately in the rat footpad just prior to induction of inflammatory pain (Yamamoto et al., 2007) . They each were found to have analgesic activity in the carrageenan and formalin pain models. The reversal of this analgesia by the group II antagonist LY341495 confirmed that this action was mediated by peripheral mGluR2 or mGluR3. These results together with the efficacy of intrathecal spinal administration of GCPII inhibitors (Yamamoto et al., 2001) , described above, suggests that NAAG might be released from and act upon pain sensitive spinal sensory peripheral neurites and their axon endings in the dorsal horn.
To examine the potential actions of NAAG above the sensory spinal axis, ZJ-43 and 2-PMPA were administered intracerebroventricularly prior to inflammatory pain induction (Yamamoto et al., 2004) . These drugs reduced both phases of the pain response in a dose dependent manner. Dissecting this activity by discrete brain regions, ZJ43 was microinjected separately into the periaqueductal gray and rostral ventromedial medulla contralateral to the formalin treated footpad (Yamada et al., 2012) . The inhibitor again reduced both phases of the pain response in a dose dependent manner. These microinjections of ZJ43 did not affect the thermal withdrawal response in the hot plate test again demonstrating a sensory selectivity to the analgesic effect. To examine the mechanism mediating analgesia, extracellular glutamate and NAAG levels were assessed in the periaqueductal gray via microdialysis (Nonaka et al., 2017) .
Systemic treatment with ZJ43 increased NAAG levels and decreased inflammation induced increases in glutamate, presumably reflecting an inhibition of synaptic release of glutamate ( Figure 1 ).
J o u r n a l P r e -p r o o f
In order to test the potential role of NAAG in the descending noradrenergic inhibitory pain pathway, a GCPII inhibitor was given systemically prior to formalin-induced inflammation of the footpad (Nonaka et al., 2017) . While reducing the pain response, the inhibitor increased the release of noradrenalin from the descending pathway into the spinal cord. The analgesia was blocked by spinal injection of an adrenergic receptor antagonist and by injection of an AMPA receptor antagonist into the locus coeruleus. As in the previous studies, these effects of GCPII inhibition were blocked by cotreatment with the group II antagonist LY341495. These data support a model in which systemic delivery of GCPIl inhibitors achieves analgesia via actions within the central nervous system culminating in activation of the descending adrenergic inhibitory pain pathway. While these studies focused on inflammatory and neuropathic pain, systemic treatment with a GCPII inhibitor also reduced the pain response in a rat model of bone cancer although much less effectively than morphine (Saito et al., 2006) . One study reported that the doses of 2-PMPA used in these and other studies resulted in total brain concentrations that were well above the IC50 values obtained for this compound in vitro (Nagel et al., 2006) .
However, direct assay of the level of inhibition of NAAG hydrolysis in vivo following systemic treatment with a standard range of ZJ43 and 2-PMPA doses provided data consistent with the conclusion that at these doses the drugs were acting via inhibition of GCPII activity .
To understand the cellular processes mediating this analgesia in the central nervous system, the roles of NAAG and GCPII were assessed in the laterocapsular part of the central nucleus of the amygdala (Adedoyin et al., 2010) . Both NAAG and a GCPII inhibitor reduced evoked post synaptic currents in these neurons following stimulation of the spinal amygdaloid afferents, an action that was blocked by a group II mGluR antagonist. This result is consistent with endogenous NAAG activation of presynaptic mGluRs to inhibit glutamate release.
Remarkably, systemic injection of the inhibitor proximal to the time of an inflammatory insult, resulted in reduction of inflammation-induce increases in transmission in this pain circuit and inflammation-induced hyperalgesia 24 hours later (Adedoyin et al., 2010) . This latter result suggests a role in blocking inflammation-induced plasticity at this synapse. The ability of open channel NMDA receptors ketamine, phencyclidine and dizocilpine (MK-801) to elicit schizophrenia-like behaviors led to a glutamate-based theory (Javitt, 2012) of this disorder that parallels the catecholamine theory (Howes, 2015) . These drugs model in mice the positive (motor activation), negative (social withdrawal) and cognitive (short-term memory) behavioral elements of the disorder (Reynolds and Neill, 2016) . Polymorphisms in mGluR3 have long been associated with schizophrenia (Eagan et al., 2004; Saini et al., 2017) and changes in GCPII and mGluR3 levels have been observed in the prefrontal cortex of schizophrenic subjects (Ghose et al., 2009) . The discovery that mGluR2/3 selective agonists moderate the effects of the PCP model of schizophrenia (Cartmell et al., 2000; Rorick-Kehn, 2017) together with recognition that NAAG activates mGluR3 Romei et al., 2013) led to testing of GCPII inhibitors in animal models of this disorder.
NAAG and Models of Schizophrenia
In the first of these studies, ZJ43 substantially reduced a series of positive behaviors induced by PCP (Olszewski et al., 2004) . In a follow up study, ZJ43 decreased positive schizophrenia-like behaviors induced by PCP and dizocilpine while also reducing a negative behavior induced by PCP in an mGluR2/3-dependent manner (Olszewski et al., 2008) . Since the mGluR2/3 antagonist could not discriminate between these two receptors as mediators of the anti-psychotic-like behavior of NAAG in these studies, ZJ43 was tested against PCP in mice that were null-mutant for either mGluR2 or mGuR3 . While PCP induced motor activation in both mouse strains, ZJ43 was only effective in the mGluR2 knock out mice and not in the mice lacking mGluR3. Confirming that GCPII was the target of these inhibitors, 2-PMPA was not effective when tested against dizocilpine induced motor activation in GCPII knock out mice . In this same study, GCPII inhibition blocked cognitive impairment induced by dizocilpine and motor activation induced by d-amphetamine. The latter result demonstrated that these inhibitors bridge the dopamine and glutamate models of this disorder. To further examine the mechanism of NAAG action in these studies, NAAG and glutamate levels were assayed in the prefrontal cortex by microdialysis . 2-PMPA and ZJ43 reduced PCP induced increase in glutamate levels but not dopamine levels while increasing extracellular levels of NAAG.
A reduction in prepulse inhibition of acoustic startle, an index of sensory processing, is consistently associated with schizophrenia in humans and in animal models of schizophrenia. In one study, ZJ43 and 2-PMPA failed to affect the deficits in prepulse inhibition induced in either J o u r n a l P r e -p r o o f the glutamate or dopamine models while a group II agonist was effective .
In another study, a structural analogue of 2-PMPA did attenuate dizocilpine-induced deficits in this sensory processing test (Takatsu et al., 2011) . Substantial differences in methods used in these two studies might well explain the apparently conflicting results.
Procognitive actions of NAAG
As noted above, GCPII inhibitors reversed the cognitive impairment induced in a model of schizophrenia . Additionally, these inhibitors: restore short-term memory in 9-month old triple transgenic Alzheimer's disease model mice (Olszewski et al., 2017) ; improve cognition in an animal model of multiple sclerosis (Rahn et al., 2012 : Hollinger et al., 2016 ; reduce cognitive failures in a model of brain trauma (Gurkoff et al., 2013) .
Similarly, mice lacking the GCPII gene are less susceptible to the cognitive loss induced by traumatic brain injury (Cao et al., 2016) . These reports of GCPII inhibitors moderating cognitive deficits in multiple models of clinical disorders suggested the possibility that NAAG/GCPII may have a more generalized precognitive action (Neale and Olszewski, 2019) . In a direct test of this hypothesis, it was found that mice treated with ZJ43 or 2-PMPA prior to acquisition trials acquired significant long-term memory that was lacking in control mice (Neale and Olszewski, 2017) . Similarly, GCPII null mutant mice have substantial long-term novel object memory while wild type mice do not (Janczura et al., 2013) . Mice treated with intoxicating doses of ethanol exhibit motor deficits that are moderated by co-treatment with GCPII inhibitors (Olszewski et al., 2017) . Confirming the role of the mGluR3 in NAAG's procognitive action, 2-PMPA reversed the cognitive deficit induced by ethanol in mGluR2 but not knock out mGluR3 mice. Additionally, mGluR3 knock out mice exhibit deficits in working memory (Lainiola et al., 2014) . Speculation as to the mechanisms through which NAAG affects cognition includes regulation of synaptic plasticity in the hippocampus (Neale and Olszewski, 2019) . For example, NAAG blocks long-term potentiation in vitro via activation of a group II receptor in the medial performant pathway of the dentate gyrus, a region where NAAG does not affect NMDA receptors (Lea et al., 2001) . In contrast, NAAG acting via presynaptic mGluR3 also impairs long-term depression at this synapse (Pöschel et al., 2005) . NAAG and other group II agonists induce long term depression in the dentate gyrus via a post-synaptic action (Huang et al., 1999) J o u r n a l P r e -p r o o f while endogenous NAAG reduces long term potentiation in the CA1 region via inhibition of NMDA receptors (Bergeron et al., 2007) . It also has been proposed that NAAG might regulate the astrocyte endothelial response to increases in neuronal activity (Baslow et al., 2013) . Data from one study suggested that activation of group II mGluRs affects memory by increasing attention (Spinelli et al., 2005) . To date, studies on the procognitive actions of GCPII inhibitors have been limited to a small number of behavioral paradigms thus providing ample opportunities for future exploration of the breadth of their effects on learning and memory.
Amyotrophic lateral sclerosis
Similar to stroke and traumatic brain injury, excess activation of glutamate receptors is considered to be a significant factor in the spinal neuron death observed in amyotrophic lateral sclerosis (Blasco et al., 2014) . Superoxide molecules, products of oxidative metabolism, are neurotoxic at high levels. These molecules increase with elevated levels of neuronal excitation as might be produced under conditions of excess glutamate release. Polymorphisms in superoxide dismutase, an enzyme that metabolizes the superoxide radical, have been found in familial cases of this disorder (Valko and Ciesla, 2019) . Utilizing mice that are transgenic for one of these familial genes and primary spinal cord cell cultures transfected with the gene, the efficacy of GCPII inhibition was tested in vivo and in vitro (Ghadge et al., 2003) . An AMPA receptor antagonist, an NMDA receptor antagonist and 2-PMPA each reduced motor neuron death in the transfected cultures in a dose dependent manner. Surprisingly, the action of 2-PMPA was not blocked by a group II mGluR, leaving unclear the mechanism of action of 2-PMPA in this cell culture model. Importantly, daily treatment with an orally available analogue of 2-PMPA significantly delayed onset of behavioral symptoms and severity of spinal pathology in superoxide dismutase transgenic mice (Ghadge et al., 2003) .
Addiction therapy
Changes in expression of mGluR2/3 receptors have been observed during different phases of cocaine addiction and withdrawal (Pomierny-Chamiolo, 2017) and selective agonists have been tested for their potential in drug addiction treatment (Moussawi and Kalivas, 2010; Cannella et al, 2013) . The first evidence of a role for NAAG in the physiology of drug addiction derived from a study in which 2-PMPA blocked induction of seizures induced by repeated J o u r n a l P r e -p r o o f cocaine administration (Witkin et al., 2002) . In a key set of studies, it was found that 2-PMPA and intranasal administration of NAAG each inhibited intravenous cocaine self-administration in dose dependent manners . Intranasal NAAG administration also reduced heroin self-administration and priming induced heroin seeking (Zhu et al., 2017) . On the other side of the addiction treatment issue, oral administration of a GCPII inhibitor reduced the probability of cocaine-induced relapse into drug seeking . The possibility that GCPII inhibitors may have impact across a range of addictive substrates is further supported by the report that 2-PMPA reduces the rewarding effects of the stimulant mehylenedioxypyrovalerone, a catecholamine reuptake inhibitor (Hicks et al., 2017) .
GCPII inhibition and bowel inflammation
While the widespread distribution of NAAG in the central and peripheral nervous system supports speculation that this peptide may be expressed in the enteric nervous system, no studies on this question have been reported to date. However, GCPII expression in the digestive tract has long been appreciated as an element in folate metabolism and mGluR2/3 immunoreactivity is highly expressed ganglia cells of the rat myenteric plexus (Larzabal et al., 1999) . Additionally, a homologue of GCPII, termed (NAALADase L) has been characterize in the rodent and human intestine (Schneider et al., 1997; Tykvart et al., 2015) . This enzyme is distinct from another homologue, GCPIII, that is expressed in the nervous system . The discovery of elevated expression of this peptidase activity in the enteric mucosa of patients with inflammatory bowel disease (Rais et al., 2016) raised the possibility that inhibitors of this enzyme might have therapeutic potential in this condition. Testing this in a mouse model of inflammatory bowel syndrome, systemic 2-PMPA was highly effective in reducing the histopathological and behavioral elements of the disorder (Date et al., 2017) . Importantly, repeated direct administration of 2-PMPA to the bowel also significantly reduced the colitis symptoms. Sufficient data has not been published to date to formulate a likely model of the mechanism of action of 2-PMPA in reducing bowel inflammation.
Inflammation: a common thread?
J o u r n a l P r e -p r o o f While this review has focused on NAAG activation of mGluR3 receptors at the level of the synapse, the potential role of this transmitter/receptor in the inflammatory response is less well studied. Application of an inflammatory stimulus to glial cell cultures induces an increase in expression of mGluR3 in microglia and astrocytes (Berger et al., 2012) suggesting that this receptor might participate in the inflammatory response in the central nervous system. The efficacy of NAAG/mGluR3 in inflammatory pain and inflammatory bowel disorder models supports the possibility that the peptide may have a broader role in moderating the inflammatory response. With respect to the other clinical conditions discussed above there are no data relating this transmitter system to inflammation. However, a role for inflammation has been proposed in addiction (Kohno et al., 2019) , schizophrenia (Khandaker et al., 2015) , Alzheimer's disease (Holmes, 2013) , traumatic brain injury (Jassam et al., 2017) and stroke (Chamorro et al., 2016) .
Additionally, proinflammatory cytokines have been associated with learning and memory decline with aging (Charlton et al.,2018) .
GCPII/PSMA as a diagnostic and therapeutic target in cancer therapy
As was noted earlier, GCPII was first identified as prostate specific membrane antigen (PSMA), a protein expressed and secreted by the human prostate (11). GCPII cleavage of vitamin B9 as well as NAAG results in the release of glutamate which stimulates oncogenic signaling via activation of mGluR1 (Kaittinas et al. 2017) . Elevated levels of glutamate have been associated with tumors and reducing glutamate levels via inhibition of glutaminase has been proposed as a therapeutic strategy (Harding et al., 2015) . Knocking down or inhibiting GCPII, alone or in combination with glutaminase inhibition, reduces glutamate levels in tumors and tumor growth (Asaka and Le, 2019; Nguyen et al., 2019) .
Additionally, GCPII is a more reliable marker of prostate cancer than the more widely known protein prostate specific antigen (PSA) (Ristau et al., 2014; O'Keefe et al., 2018) . As a result, this cell surface protein provides a means of targeting hyperplasic prostate cells. One approach has involved coupling drugs to anti-PSMA antibodies (Olson and Israel, 2014 ). An alternative approach that emerged from the synthesis and characterization of ZJ43 as a drug with high affinity for PSMA (Kozikowski et al., 2001) was the development of ZJ43 derivatives for nuclear imaging of the prostate (Zhuo et al., 2005 , Mease et al., 2008 , Wang et al., 2018a and J o u r n a l P r e -p r o o f for tracking metastatic prostate cancer (Carducci et al., 2012; Cho et al., 2012) . Following up on this, other novel compounds have been developed for tracing PSMA expressing cells via nuclear and fluorescence methods (O'Keefe et al., 2018; Schottelius et al., 2019) . Less well advanced but potentially promising is the development of high affinity radioligands for PSMA for prostate cancer radiotherapy (Wang et al, 2018a; Wang et al., 2018b) . Of broader significance, the expression of PSMA on the surface of the neovascular endothelium of non-prostate tumors (Backhous et al., 2018) might provide opportunities for use of these high affinity ligands in diagnosis and radionuclide therapy for other cancers (Kovalinka, 2019) .
Challenges in Moving From Basic Preclinical Research to Clinical Trials.
Nearly all of the research on NAAG and GCPII inhibition cited in this review was based on grant supported research, much of it from the US, National Institutes of Health. This body of data provides a clear and coherent rationale for developing NAAG peptidase inhibitors through the next levels of preclinical and clinical trials in order to examine their value in a series of disorders. There are, however, several difficulties associated with acting on this rationale.
Additional GCPII inhibitors will have to be developed inasmuch as the GCPII inhibitors reported to date do not have high penetrance of the blood brain barrier and as a result would likely have to be delivered intranasally in humans (Rais et al., 2015) . Thus, the development and patenting of a novel GCPII inhibitor with high brain penetrance will provide substantial inducement for the substantial investment required to pursue human therapies. Additionally, for drug development to move forward, it is important to understand in greater detail the downstream cellular mechanisms that mediate the actions of GCPII inhibition in each animal model. The absence of mGluR3 selective agonists and antagonists excepting NAAG and beta-NAAG (Lea et al, 2001) respectively has limited progress in this area of neurochemistry beyond an appreciation of the receptor's regulation of adenylate and guanylate cyclase (Wroblewska et al., 1998 (Wroblewska et al., , 2006 ) and NAAG's inhibition of transmitter release via presynaptic receptors (Zhao et al., 2001; Sanabria et al., 2004; Romei et al., 2013) . A final drawback to acting on this rationale is the risk inherent in extrapolating from data from animal models to human trials.
Development of new drugs for stroke and traumatic brain injury suffer the handicap that each subject in a clinical trial will have a somewhat different insult and time between the insult and treatment and each subject will likely recover to some degree without treatment. As a result, J o u r n a l P r e -p r o o f the variance in recovery within drug treated and placebo treated groups will be large such that drugs with moderate efficacy will be difficult to identify statistically. Advancing GCPII inhibitors further with the aim at treating symptoms of schizophrenia is handicapped by recognition that the animal models differ substantially from the human condition. Schizophrenia is a neurodevelopmental disorder that typically emerges in young adulthood while the high doses of open channel NMDA antagonists and the dopamine releasing drugs like amphetamine rapidly induce "schizophrenia-like" behavioral effects. Not surprisingly, drugs developed via these models have not been sufficiently successful in human trials to warrant use in the clinic and as a consequence there may be little enthusiasm for investing in GCPII inhibitors as potential antipsychotic drugs. Similarly, studies in the transgenic mouse models of Alzheimer's disease have yielded some positive results, none have proven effective in clinical trials raising questions as to the significance of positive data from the mouse models. With respect to NAAG's effects in one of these models, it seems likely that the procognitive effect is generalized rather than specific to this model of Alzheimer's. Contrasting data on changes in NAAG levels with disease onset in one such mouse model with that from human Alzheimer's subjects, further emphasizes the difficulty with extrapolating from such models (Hollinger et al., 2019) .
The one clinical application for GCPII inhibitors with the greatest immediate potential is as analgesic drugs. The animal models well replicate the human condition and within individual testing provides a high level of statistical validity. Two decades after NAAG was first fully recognized as a neurotransmitter (Neale et al., 2000) , it now is time to consider the investments that will take this knowledge to the clinic.
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